BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
BioLineRx and partner Hemispherian dosed the first patient in a Phase 1/2a study of GLIX1 for recurrent and progressive glioblastoma. The first-in-human trial will enroll up to 30 patients to establish safety and dosing, with Phase 1 data anticipated in the first half of 2027.
Key figures
- Drug Name
- GLIX1
- Phase Of Trial
- Phase 1/2a
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.